File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Tumour Growth-Suppressive Effect of Arsenic Trioxide in Squamous Cell Lung Carcinoma

TitleTumour Growth-Suppressive Effect of Arsenic Trioxide in Squamous Cell Lung Carcinoma
Authors
Issue Date2017
PublisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ol
Citation
Oncology Letters, 2017, v. 14 n. 3, p. 3748-3754 How to Cite?
AbstractSquamous cell lung carcinoma (SCC) is the second commonest subtype of non-small cell lung carcinoma. The anticancer effects of arsenic trioxide (ATO) in lung adenocarcinoma and small cell lung carcinoma have been reported while in SCC are unknown. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and Western blot were used to determine cell viability and protein expression respectively. Phosphatidylserine externalization, mitochondrial membrane depolarization and cell cycle distribution were studied using flow cytometry. The in vivo effect of ATO was investigated with a xenograft model. SK-MES-1 and SW900 SCC cells were sensitive to clinically relevant concentrations of ATO. ATO induced apoptosis, mitochondrial membrane depolarization, G2/M arrest, downregulation of XIAP, Bcl-2, E2F1, thymidylate synthase and RRM1 as well as upregulation of Bak, cleaved PARP and cleaved caspase 3 in a cell-line specific manner. In SW900 xenograft model, tumour growth was inhibited by ATO with formation of apoptotic bodies and downregulation of Bcl-2 and E2F1. In conclusion, ATO suppressed growth of SCC in vitro and in vivo.
Persistent Identifierhttp://hdl.handle.net/10722/227365
ISSN
2015 Impact Factor: 1.482
2015 SCImago Journal Rankings: 0.626

 

DC FieldValueLanguage
dc.contributor.authorLEUNG, LL-
dc.contributor.authorLam, SK-
dc.contributor.authorLi, YV-
dc.contributor.authorHo, JCM-
dc.date.accessioned2016-07-18T09:10:02Z-
dc.date.available2016-07-18T09:10:02Z-
dc.date.issued2017-
dc.identifier.citationOncology Letters, 2017, v. 14 n. 3, p. 3748-3754-
dc.identifier.issn1792-1074-
dc.identifier.urihttp://hdl.handle.net/10722/227365-
dc.description.abstractSquamous cell lung carcinoma (SCC) is the second commonest subtype of non-small cell lung carcinoma. The anticancer effects of arsenic trioxide (ATO) in lung adenocarcinoma and small cell lung carcinoma have been reported while in SCC are unknown. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and Western blot were used to determine cell viability and protein expression respectively. Phosphatidylserine externalization, mitochondrial membrane depolarization and cell cycle distribution were studied using flow cytometry. The in vivo effect of ATO was investigated with a xenograft model. SK-MES-1 and SW900 SCC cells were sensitive to clinically relevant concentrations of ATO. ATO induced apoptosis, mitochondrial membrane depolarization, G2/M arrest, downregulation of XIAP, Bcl-2, E2F1, thymidylate synthase and RRM1 as well as upregulation of Bak, cleaved PARP and cleaved caspase 3 in a cell-line specific manner. In SW900 xenograft model, tumour growth was inhibited by ATO with formation of apoptotic bodies and downregulation of Bcl-2 and E2F1. In conclusion, ATO suppressed growth of SCC in vitro and in vivo.-
dc.languageeng-
dc.publisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ol-
dc.relation.ispartofOncology Letters-
dc.titleTumour Growth-Suppressive Effect of Arsenic Trioxide in Squamous Cell Lung Carcinoma-
dc.typeArticle-
dc.identifier.emailLam, SK: sklam77@hku.hk-
dc.identifier.emailHo, JCM: jhocm@hku.hk-
dc.identifier.authorityHo, JCM=rp00258-
dc.identifier.doi10.3892/ol.2017.6646-
dc.identifier.hkuros259323-
dc.identifier.volume14-
dc.identifier.issue3-
dc.identifier.spage3748-
dc.identifier.epage3754-
dc.publisher.placeGreece-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats